InspireMD (NSPR) Competitors $2.87 -0.18 (-5.90%) (As of 12:57 PM ET) Add Compare Share Share Competitors Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsTrends NSPR vs. CATX, ZYXI, LUNG, ELMD, PROF, SGHT, DRTS, NYXH, SKIN, and KRMDShould you be buying InspireMD stock or one of its competitors? The main competitors of InspireMD include Perspective Therapeutics (CATX), Zynex (ZYXI), Pulmonx (LUNG), Electromed (ELMD), Profound Medical (PROF), Sight Sciences (SGHT), Alpha Tau Medical (DRTS), Nyxoah (NYXH), Beauty Health (SKIN), and KORU Medical Systems (KRMD). These companies are all part of the "medical equipment" industry. InspireMD vs. Perspective Therapeutics Zynex Pulmonx Electromed Profound Medical Sight Sciences Alpha Tau Medical Nyxoah Beauty Health KORU Medical Systems InspireMD (NYSE:NSPR) and Perspective Therapeutics (NYSE:CATX) are both small-cap medical companies, but which is the better business? We will contrast the two companies based on the strength of their profitability, institutional ownership, media sentiment, earnings, risk, analyst recommendations, dividends, valuation and community ranking. Is NSPR or CATX more profitable? InspireMD has a net margin of -413.96% compared to Perspective Therapeutics' net margin of -4,096.66%. Perspective Therapeutics' return on equity of -27.40% beat InspireMD's return on equity.Company Net Margins Return on Equity Return on Assets InspireMD-413.96% -69.42% -57.68% Perspective Therapeutics -4,096.66%-27.40%-23.16% Does the MarketBeat Community believe in NSPR or CATX? Perspective Therapeutics received 15 more outperform votes than InspireMD when rated by MarketBeat users. Likewise, 94.74% of users gave Perspective Therapeutics an outperform vote while only 3.85% of users gave InspireMD an outperform vote. CompanyUnderperformOutperformInspireMDOutperform Votes33.85%Underperform Votes7596.15% Perspective TherapeuticsOutperform Votes1894.74% Underperform Votes15.26% Which has more risk & volatility, NSPR or CATX? InspireMD has a beta of 0.98, indicating that its stock price is 2% less volatile than the S&P 500. Comparatively, Perspective Therapeutics has a beta of 1.13, indicating that its stock price is 13% more volatile than the S&P 500. Do institutionals and insiders believe in NSPR or CATX? 44.8% of InspireMD shares are held by institutional investors. Comparatively, 54.7% of Perspective Therapeutics shares are held by institutional investors. 29.7% of InspireMD shares are held by insiders. Comparatively, 3.5% of Perspective Therapeutics shares are held by insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a stock will outperform the market over the long term. Which has better earnings and valuation, NSPR or CATX? InspireMD has higher revenue and earnings than Perspective Therapeutics. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioInspireMD$6.20M12.66-$19.92M-$0.75-4.01Perspective Therapeutics$1.43M195.21-$46.51MN/AN/A Do analysts recommend NSPR or CATX? InspireMD presently has a consensus price target of $4.50, indicating a potential upside of 49.50%. Perspective Therapeutics has a consensus price target of $15.14, indicating a potential upside of 266.66%. Given Perspective Therapeutics' higher probable upside, analysts plainly believe Perspective Therapeutics is more favorable than InspireMD.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score InspireMD 0 Sell rating(s) 0 Hold rating(s) 1 Buy rating(s) 0 Strong Buy rating(s) 3.00Perspective Therapeutics 0 Sell rating(s) 1 Hold rating(s) 8 Buy rating(s) 0 Strong Buy rating(s) 2.89 Does the media favor NSPR or CATX? In the previous week, Perspective Therapeutics had 10 more articles in the media than InspireMD. MarketBeat recorded 11 mentions for Perspective Therapeutics and 1 mentions for InspireMD. Perspective Therapeutics' average media sentiment score of 0.54 beat InspireMD's score of 0.49 indicating that Perspective Therapeutics is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment InspireMD 0 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral Perspective Therapeutics 5 Very Positive mention(s) 0 Positive mention(s) 3 Neutral mention(s) 1 Negative mention(s) 0 Very Negative mention(s) Positive SummaryPerspective Therapeutics beats InspireMD on 11 of the 16 factors compared between the two stocks. Ad Timothy SykesTim Sykes’ Urgent Trade Alert: “Make this move now”WARNING: 80 Wall Street banks are gearing up for MASSIVE D.C. shock This $2 trillion D.C. shock is NOT about Trump or Biden dropping out of the race…Click here to see a unique election-year trade Get InspireMD News Delivered to You Automatically Sign up to receive the latest news and ratings for NSPR and its competitors with MarketBeat's FREE daily newsletter. Email Address New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding {thisCompany.Symbol} and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NYSE and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart NSPR vs. The Competition Export to ExcelMetricInspireMDSurgical & medical instruments IndustryMedical SectorNYSE ExchangeMarket Cap$78.50M$4.48B$5.20B$20.43BDividend YieldN/A42.91%5.23%3.44%P/E Ratio-4.0112.5585.7136.62Price / Sales12.6650.591,469.4219.07Price / CashN/A55.4235.2918.69Price / Book1.645.374.915.73Net Income-$19.92M$13.65M$117.36M$983.96M7 Day PerformanceN/A2.33%2.75%0.64%1 Month Performance21.37%7.00%1.71%6.62%1 Year Performance24.90%45.76%36.01%24.56% InspireMD Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)NSPRInspireMD2.3693 of 5 stars$2.87-5.9%$4.50+56.8%+26.6%$74.85M$6.20M-3.8350CATXPerspective Therapeutics3.4194 of 5 stars$4.16-4.4%$15.14+264.0%N/A$281.17M$1.43M0.00116ZYXIZynex3.8575 of 5 stars$8.17-1.8%$14.00+71.4%-9.1%$260.21M$184.32M55.471,100LUNGPulmonx3.0645 of 5 stars$6.41-0.6%$14.67+128.8%-41.9%$253.12M$79.30M-4.39250ELMDElectromedN/A$29.77-3.3%N/A+188.3%$251.85M$54.72M42.75174PROFProfound Medical2.5723 of 5 stars$8.49+4.6%$13.75+62.0%-23.0%$209.38M$8.98M-6.06150SGHTSight Sciences3.4449 of 5 stars$4.04+1.3%$5.50+36.1%+38.6%$205.05M$79.54M-3.92210Positive NewsDRTSAlpha Tau Medical3.06 of 5 stars$2.91+3.9%$8.00+174.9%-4.4%$203.48MN/A-6.5180Positive NewsNYXHNyxoah3.4258 of 5 stars$7.94-3.9%$17.00+114.1%+61.9%$198.02M$5.08M-4.27146Gap DownSKINBeauty Health3.0312 of 5 stars$1.53+3.4%$2.55+66.7%-46.7%$189.90M$398M-3.521,030Positive NewsKRMDKORU Medical Systems1.3581 of 5 stars$3.98flat$4.13+3.6%+73.8%$182.43M$31.99M-15.9280 Related Companies and Tools Related Companies CATX Competitors ZYXI Competitors LUNG Competitors ELMD Competitors PROF Competitors SGHT Competitors DRTS Competitors NYXH Competitors SKIN Competitors KRMD Competitors Top 10 Stock Comparisons Bank Stocks Artificial Intelligence Stocks Toy Stocks Growth Stocks Airline Stocks Chinese Stocks EV Charging Stocks Defense Stocks Lithium Stocks Pharmaceutical Stocks This page (NYSE:NSPR) was last updated on 12/3/2024 by MarketBeat.com Staff From Our PartnersTim Sykes’ Urgent Trade Alert: “Make this move now”WARNING: 80 Wall Street banks are gearing up for MASSIVE D.C. shock This $2 trillion D.C. shock is NOT abou...Timothy Sykes | SponsoredMusk’s new company could top a trillion?The investment legend who predicted the rise of Bitcoin, Facebook and streaming services like Netflix… Just...Paradigm Press | SponsoredHow this >10-cent coin is going to outperform Bitcoin Chris Rowe – the man who recommended Amazon in 1998… Bitcoin and Ethereum in 2017… And has spotted 44 diffe...True Market Insiders | SponsoredElon Musk’s chilling warning for humanityThe 'invasion' I've discovered has nothing to do with the border crisis. What's happening at our southern bord...The Freeport Society | SponsoredThe #1 Crypto for AIWe’ve issued an urgent landmark trade alert for a new crypto wonder. So, I decided to give you this heads-u...Weiss Ratings | SponsoredIs NVDA a sell? Buy this stock instead before Dec 3After months of speculation that Nvidia was "cooling off..." and "running out of steam..." The company is m...Chaikin Analytics | SponsoredEven Trump can’t stop what’s coming.No matter who sits in the White House over the next four years, a series of events has been triggered that cou...Behind the Markets | SponsoredBuffett's Oil Bet + This 22% Dividend PlayWarren Buffett has been quietly amassing a massive position in oil stocks. But while Buffett's picks (Occid...Investors Alley | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding InspireMD, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share InspireMD With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Free NSPR Stock Alerts